AI Proteins, Non-Food Materials: Weekly Bio-Manufacturing Funding Roundup | Investors Find Projects Here...
This week, investment and financing activity in the biomanufacturing sector continues to surge. According to incomplete statistics, between 7/13 and 7/17, multiple biomanufacturing-related companies announced new rounds of funding, coveringAI-Driven Biological Breeding、AI-driven protein design, non-food bio-based materials, and dietary supplement ingredientsamong other specialized areas.
As capital flows into bio-manufacturing, an industry transformation driven by "intelligent manufacturing" is accelerating. In this context,8 27-28, the 2nd Yimao Bio-Manufacturing Industry Conference & Exhibition (Summer) will be held in Shanghai.This will undoubtedly serve as the best window to observe the latest trends in this sector.
Neubio completes nearly 2 billion C+ round financing to develop dietary nutrition ingredients using innovative drug R&D logic
Nebio Biopharma has completed a C+ round of financing totaling nearly 2 billion yuan, led by China Life Equity Investments with participation from existing shareholder Mingxi Capital. This marks the company's second funding round exceeding 100 million yuan within six months. Nebio Biopharma is dedicated to...Dietary Supplement Ingredient R&DCumulatively launched over 40 original raw materials, with a research pipeline exceeding 100 products, coveringSports Nutrition, Weight Management, Cognitive Health, Anti-Agingand other fields, the companyIn-house formulation factory, biomanufacturing facilityand plans to construct a comprehensive factory spanning over 200 acres with an annual production capacity of 10,000 tons. The funds raised in this round will primarily be used for product R&D and the construction of the new factory.
AI-driven breeding platform company Tian Neng Jingxiu completes tens of millions of yuan in Series A funding
Recently, Sichuan Tianneng Jingxiu Biotechnology Co., Ltd., a leading domestic AI-driven biological breeding platform company, announced the completion of its tens-of-millions-of-yuan Series A financing round. The investment was led by Guanghua Wutong, Tianlai Fund, Boruidi, Sichuan Rural Revitalization Fund, and Haochen Capital, with Kaicheng Capital serving as the financial advisor for the transaction. The company focuses onTechnical Services for Maintainer Line Multiplication and Backcross BreedingTwo core business segments will enter a phase of explosive commercial growth over the next two years as the production area for male-sterile lines continues to expand.
AI-Driven Protein R&D Platform Tianwu Technology Closes Hundreds of Million RMB Series A++ Financing
On 7 13, Tianwu Technology announced the completion of its A++ round financing, totaling hundreds of millions of yuan. The round was jointly led by Shanghai State-owned Assets Investment & Leading and SDIC Innovation, with participation from Juji Microfibers, Jinjing Capital, and continued investment from existing shareholders Qiming Venture Partners, Yonghua Investment, and Shanghai Science & Technology Innovation Fund. Tianwu Technology is an AI-driven, full-stack protein R&D platform company; this funding will be primarily used forAI technology iteration and continuous R&D of our core product, Xiaowu™and accelerate AI-driven protein design capabilities inCircular Economy, Innovative Drugs, Big Health, Medical Consumablesscaling applications in these fields, further advancing AI for Science from lab research to industrial deployment.
Hanhe Biosecures Funding from China Innovation Capital and Xingxiang Capital to Break Through with "Made in China" Solution: Replacing Petroleum with Agricultural and Forestry Waste
Hanhe Bio announces completion of tens-of-millions RMB strategic financing round, led by Guoke Venture Capital with follow-on investment from funds under Xingxiang Capital. Funds will be allocated specifically forHunan Anxiang Ecological Reed Negative-Carbon Bio-Manufacturing New Materials Project with Annual Capacity of 5 Million TonsHanhe Biotechnology is a high-tech enterprise integrating bio-refining and new material R&D and production, with an establishedBiorefinery Technology Systems and New Biomass Materials from Non-Food FeedstocksFocus areas: Establishing an end-to-end technical pathway from agricultural and forestry waste to bio-resins, bioplastics, and new anode materials.
Jinhe Bio 3 billion yuan private placement completed; raised funds to boost environmental protection and warehousing initiatives
On 7 15, King River Bio completed a private placement raising 3 billion yuan, of which 3 billion yuan will be invested inTwo major corporate projects and supplementary working capitalGold, the physical projects include the sewage treatment capacity expansion and water resource regeneration upgrade project, as well as a new product warehouse construction project (grain reserve depot). In terms of emerging business layout, Jinhe Bio disclosed its investment plan in 6, proposing to invest 5.5 billion yuan to build an annual production capacity of... in the Tuoketuo Economic Development Zone, Inner Mongolia.10000 tons oxytetracycline, 20000 tons Coenzyme Q10 intermediateFlexible production and construction project, positioned to supply basic raw materials to downstream manufacturers, leveraging existingFermentation technology reserves and production facilitiesRetrofit for rapid capacity ramp-up.
Why is capital heavily investing in bio-manufacturing?
According to a dynamic analysis report on the bio-manufacturing industry released by relevant institutions, 2026 years ago in the first 5 months, China's bio-manufacturing sector experienced a total ofFrom 170Funding event, total disclosed funding amountOver 230 billion yuanAs a core track of new quality productive forces, biomanufacturing is leveraging cutting-edge technologies such as synthetic biology, green fermentation, and bio-synthesis to reshapeFood, Materials, Environmental Protection, Biomedicinethe entire industry chain.
This week's funding events highlight three key trends: AI-driven biomanufacturing is the hottest investment area, green and low-carbon initiatives are deeply aligned with "dual carbon" goals, and the ability to commercialize innovations has become a core criterion for investors.
As capital flows accelerate, the industry needs a high-quality platform to connect resources and gain trend insights.
2026 (2nd) Yimao Bio-Manufacturing Industry Conference & Exhibition (Summer) will be held in Shanghai from 8 to 28., the conference is organized byYimao MedicalHostShanghai Future Industry Bio-manufacturing Special Committee, Shanghai Society of BioengineeringTo support the unit,blue rainbowFor partners, on-site invitations will be extended2000+ Attendees,100+Speaker,20+ Premium Exhibitors, featuring "Conference - Exhibition - Meeting - EventFour core modules focused on "fundamental research breakthroughs + cross-domain industrial implementation," providing comprehensive coverage.Medicine & Aesthetics, Bio-based Materials & Green Chemicals, Food & Agriculture, AI-Enabled SolutionsCore Areas.
